Immunic (NASDAQ:IMUX – Get Free Report) announced its quarterly earnings results on Friday. The company reported ($0.99) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.79) by ($0.20), FiscalAI reports.
Immunic Trading Down 3.5%
Shares of IMUX traded down $0.27 during midday trading on Friday, hitting $7.52. 105,145 shares of the company’s stock traded hands, compared to its average volume of 283,926. Immunic has a 1 year low of $5.06 and a 1 year high of $17.43. The firm’s fifty day moving average is $8.70 and its 200-day moving average is $11.52. The stock has a market capitalization of $102.57 million, a price-to-earnings ratio of -1.72 and a beta of 1.48.
Trending Headlines about Immunic
Here are a few of the latest headlines about IMUX:
- Positive Sentiment: The company said its pivotal ENSURE-1 and ENSURE-2 trials remain on track to report top-line results in December. It also expects its funding to last into late 2027, giving it runway beyond the upcoming readout. Article: Immunic on track for December Phase 3 readout in relapsing MS, funded into late 2027
- Neutral Sentiment: Immunic is preparing to start its Phase 3 PROTECT-MS trial for progressive MS, with first-patient enrollment expected in the first half of 2027. The company also announced leadership appointments intended to support regulatory and commercial readiness. Article: Immunic reports third-quarter 2026 financial results and provides corporate update
- Negative Sentiment: Third-quarter results showed a $42.3 million net loss, with a loss of $0.99 per share—worse than the $0.79 loss analysts expected. Coverage cited higher expenses and the earnings miss as reasons for investor concern. Article: Immunic Q3 loss widens on higher expenses
Wall Street Analysts Forecast Growth
A number of brokerages recently weighed in on IMUX. Ladenburg Thalmann & Co. Inc. upgraded Immunic to a “strong-buy” rating in a research note on Wednesday, July 29th. Zacks Research lowered Immunic from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, November 10th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Immunic in a research note on Wednesday, August 26th. Roth Capital reiterated a “buy” rating on shares of Immunic in a report on Tuesday, September 1st. Finally, Wedbush reiterated an “outperform” rating and issued a $45.00 target price on shares of Immunic in a report on Thursday, September 10th. Three research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $35.43.
Check Out Our Latest Analysis on IMUX
Immunic Company Profile
Immunic, Inc. is a clinical-stage biopharmaceutical company developing oral small-molecule treatments for chronic inflammatory and autoimmune diseases. The company’s research focuses on therapies intended to address conditions with significant unmet medical needs. Its lead drug candidate, vidofludimus calcium, is being developed for multiple sclerosis. Immunic is also advancing other investigational compounds, including IMU-856, which is being studied for its potential to support intestinal barrier function in gastrointestinal diseases.
Read More
- Five stocks we like better than Immunic
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Immunic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunic and related companies with MarketBeat.com's FREE daily email newsletter.
